60,571 results match your criteria Myeloma


Clinical features and treatment outcome of elderly multiple myeloma patients with impaired renal function.

J Clin Lab Anal 2019 Apr 19:e22888. Epub 2019 Apr 19.

Department of Hematology, Tianjin Medical University General Hospital, Tianjin, China.

Background: Renal impairment (RI) is a most common complication of multiple myeloma (MM), which is associated with an increased risk of early death and worse survival.

Methods: We retrospectively analyzed clinical features and outcomes of 77 MM patients over 70 years old and compared the differences between with and without RI groups.

Results: The percentage of elder MM patients with RI was 61%. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jcla.22888DOI Listing

A significant incidental finding on cone beam computed tomography: multiple myeloma.

Aust Dent J 2019 Apr 19. Epub 2019 Apr 19.

Private Practice, Perth, Western Australia, Australia.

Cone beam computed tomography is widely used in dentistry. Incidental findings are common, with many requiring intervention or monitoring. We present a rare case of previously undiagnosed, asymptomatic multiple myeloma first identified incidentally on cone beam computed tomography and panoramic radiography. Read More

View Article

Download full-text PDF

Source
https://onlinelibrary.wiley.com/doi/abs/10.1111/adj.12695
Publisher Site
http://dx.doi.org/10.1111/adj.12695DOI Listing
April 2019
1 Read

Exploring the Drug Repurposing Versatility of Valproic Acid as a Multifunctional Regulator of Innate and Adaptive Immune Cells.

J Immunol Res 2019 14;2019:9678098. Epub 2019 Mar 14.

Subdirección de Investigación Básica, Instituto Nacional de Cancerología (INCan), México City, Mexico.

Valproic acid (VPA) is widely recognized for its use in the control of epilepsy and other neurological disorders in the past 50 years. Recent evidence has shown the potential of VPA in the control of certain cancers, owed in part to its role in modulating epigenetic changes through the inhibition of histone deacetylases, affecting the expression of genes involved in the cell cycle, differentiation, and apoptosis. The direct impact of VPA in cells of the immune system has only been explored recently. Read More

View Article

Download full-text PDF

Source
https://www.hindawi.com/journals/jir/2019/9678098/
Publisher Site
http://dx.doi.org/10.1155/2019/9678098DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6437734PMC
March 2019
1 Read

Presentation Patterns, Diagnostic Markers, Management Strategies, and Outcomes of IgD Multiple Myeloma: A Systematic Review of Literature.

Cureus 2019 Feb 4;11(2):e4011. Epub 2019 Feb 4.

Internal Medicine, The University of Arizona, Tucson, USA.

Immunoglobulin (Ig) D multiple myeloma (MM) is a rare subtype of MM comprising 2% of all the cases. Malignant plasma cell invasion leads to signs and symptoms similar to other subtypes of MM. The synthesis rate of IgD is lower in IgD MM patients, making it very difficult to diagnose compared to other subtypes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7759/cureus.4011DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6450588PMC
February 2019

Correlations Between Imaging Biomarkers and Proliferation Index Ki-67 in Lymphomas: A Systematic Review and Meta-Analysis.

Clin Lymphoma Myeloma Leuk 2019 Mar 11. Epub 2019 Mar 11.

Department of Diagnostic and Interventional Radiology, University of Leipzig, Leipzig, Germany.

Background: Few studies investigated relationships between positron emission tomography (PET) as well as diffusion-weighted imaging (DWI) with proliferating index Ki-67 in lymphomas. The aim of the present analysis was to review the published results and perform a meta-analysis to provide data on the associations between standardized uptake values (SUV) derived from PET as well as apparent diffusion coefficient (ADC) derived from DWI with Ki-67 index in lymphomas.

Materials And Methods: The MEDLINE library was screened for relationships between PET and DWI with Ki-67 in lymphoma up to October 2018. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2019.03.005DOI Listing

Multiple myeloma immunophenotyping: method validation.

Ann Biol Clin (Paris) 2019 Apr;77(2):197-217

IUC-T laboratoire d'hématologie, CHU de Toulouse, Toulouse, France.

Flow cytometric immunophenotyping has become essential for management of multiple myeloma (assessment of clonality, prognostic information on the risk of progression in gammopathy of undetermined significance, minimal residual disease monitoring). Immunophenotyping of bone marrow plasma cells is routinely used in the haematology laboratory of the University Hospital of Toulouse. To guarantee the reliability of this technique, the laboratory decided to check this method in compliance with the NF ISO EN 15189, standard for medical laboratories requirements. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1684/abc.2019.1426DOI Listing

[Significance of Neutrophil/Lymphocyte Ratio in the Prognosis of Patients with Multiple Myeloma].

Zhongguo Shi Yan Xue Ye Xue Za Zhi 2019 Apr;27(2):489-493

Department of Hematology, Gansu Provincial People's Hospital, Lanzhou 730000, Gansu Province, China.

Objective: To study the value of neutrophil/lymphocyte ratio (NLR) in the evaluation of prognosis of patients with multiple myeloma (MM).

Methods: NLR was calculated on the basis of the blood routine examination results of 65 patients with primary MM (MM group) and 83 persons receiving physical examination as control group, and the difference in 2 group was compared; moreover according to the median as threshold, the patients were divided into low NLR group (NLR<2.34) and high NLR group (NLR≥2. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.19746/j.cnki.issn.1009-2137.2019.02.029DOI Listing

[Effect of Bushen Yanggu Decoction on Multidrug Resistance of Multiple Myeloma Cell Line KM3/BTZ].

Zhongguo Shi Yan Xue Ye Xue Za Zhi 2019 Apr;27(2):482-488

Department of Orthopedics The Third Affiliated Hospital of Guangzhou University of Tranditional Chinese Medicine;Guangzhou 510000, Guangdong Province, China, E-mail:

Objective: To explore the effect of Bushen Yanggu Decoction (BYD) on drug resistance and proliferation of human multiple myeloma-resistant KM3/BTZ cells.

Methods: Human multidrug-resistant KM3/BTZ cells were established by Bortezomib (BTZ) gradient induction. The effects of commonly used chemotherapeutic drugs and serum containing Bushen Yanggu Decoction (BYD) on the proliferation of KM3 cells and KM3/BTZ cells were detected by MTT assay. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.19746/j.cnki.issn.1009-2137.2019.02.028DOI Listing

[Effect of siRNA-Interfering β-Catenin Expression on MDR of Human Multiple Myeloma Cell Line].

Zhongguo Shi Yan Xue Ye Xue Za Zhi 2019 Apr;27(2):477-481

Department of Orthopedics, The Third Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou 510000, Guangdong Province, China,E-mail:

Objective: To investigate the effecr of siRNA-interfering β-catenin expression on drug-resistance of multiple myeloma cells.

Methods: The multiple myeloma cell line RPMI-8226 was cultured in vitro. The maphalan-resistant cell model was established by concentration gradient ascending of durg, then the drug-resistant cell line was instantaneously transfected with β-catenin siRNA, the sensitivity of RPMI 8226 cells to maphalan was detected by CCK-8 meltod before and after the transfection with siRNA; the mRNA and protein expression of β-catenin was detected by qRT-PCR and Western blot respectively, the apoptosis of cells was detected by flow cytometry. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.19746/j.cnki.issn.1009-2137.2019.02.027DOI Listing
April 2019
1 Read

[Significance of Detecting Serum Complement C3 and C4 in Patients with Multiple Myeloma].

Zhongguo Shi Yan Xue Ye Xue Za Zhi 2019 Apr;27(2):472-476

Department of Hematology, Chaohu Hospital Affiliated to Anhui Medical University,Chaohu 238000, Anhui Province, China.

Objective: To investigate the significance of detecting serum complement C3 and C4 in patients with multiple myeloma (MM) and to explore its correlation with myeloma bone disease (MBD).

Methods: The levels of serum complement C3 and C4 in 69 MM patients and 30 healthy people were examined by scatter nephelometry. The bone density of L1-4 vertebral body, bilateral femoral neck and bilateral hip joints were measured by dual energy bone density meter (DXA). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.19746/j.cnki.issn.1009-2137.2019.02.026DOI Listing

[Curcumin Increases the Chemosensitivity of Multiple Myeloma to Bortezomib by Inhibiting the Notch1 Signaling Pathway].

Zhongguo Shi Yan Xue Ye Xue Za Zhi 2019 Apr;27(2):464-471

Department of Hematology, The Second Affiliated Hospital of Soochow University, Suzhou 215006, Jiangsu Province, China,E-mail:

Objective: To evaluated the effect of curcumin on the bortezomib-resistant myeloma cells and the expression of Notch1 signaling pathway, in order to further explore its potential mechanism.

Methods: Curcumin, bortezomib, and curcumin combined bortezomib were added into RPMI 8266, U266, 5 nmol/L bortezomib-resistant RPMI 8266 (RPMI 8226-V5R), 5 nmol/L bortezomib-resistant U 266 (U266-V5R) and CD138+ plasma cells respectively. The cell proliferation was measured by MTT assay. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.19746/j.cnki.issn.1009-2137.2019.02.025DOI Listing

[Effects of Oridonin on Proliferation Apoptosis of Human Multiple Myeloma Cells H929 in Vitro].

Zhongguo Shi Yan Xue Ye Xue Za Zhi 2019 Apr;27(2):458-463

Department of Hematology, Affiliated Hospital, Nanjing University of Traditional Chinese Medicine, Nanjing 210029, Jiangsu Province, China,E-mail:

Objective: To investigate the effects of oridonin (ORI) on the proliferation and apoptosis of human multiple myeloma cell line H929 and its possible mechanism.

Methods: H929 cells were exposed to ORI 0、4、8、12、16、20、24、28、32 μmol/L for 12, 24 and 36 hours respectively. The prolifcration inhibitory effect of ORI on H929 cells was determined by MTT assay and then the working concentrations of ORI were determined. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.19746/j.cnki.issn.1009-2137.2019.02.024DOI Listing
April 2019
1 Read

Acute non-heparin-induced thrombocytopenia during hemodiafiltration in a patient with multiple myeloma.

Clin Case Rep 2019 Apr 22;7(4):699-702. Epub 2019 Feb 22.

Department of Clinical Laboratory Kyoto University Hospital Kyoto Japan.

This report demonstrates that not only heparin-induced thrombocytopenia, but also hemodialysis conditions (platelet activation due to hemodiafiltration and heparin underdosing) may markedly reduce the platelet count and cause clotting in the hemodialysis circuit in patients in a hypercoagulable state. The clot prevention effects of bortezomib are therefore of great importance. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ccr3.1997DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6452500PMC

Identification of the 2-Benzoxazol-2-yl-phenol Scaffold as New Hit for JMJD3 Inhibition.

ACS Med Chem Lett 2019 Apr 25;10(4):601-605. Epub 2019 Feb 25.

Department of Pharmacy, University of Salerno, Via Giovanni Paolo II, 132, I-84084 Fisciano, Salerno, Italy.

JMJD3 is a member of the KDM6 subfamily and catalyzes the demethylation of lysine 27 on histone H3 (H3K27). This protein was identified as a useful tool in understanding the role of epigenetics in inflammatory conditions and in cancer as well. Guided by a virtual fragment screening approach, we identified the benzoxazole scaffold as a new hit suitable for the development of tighter JMJD3 inhibitors. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1021/acsmedchemlett.8b00589DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6466828PMC

Oligosecretory Primary Plasma Cell Leukemia with Atypical Morphological Abnormality.

Intern Med 2019 Apr 17. Epub 2019 Apr 17.

Department of Hematology, Atomic Bomb Disease Institute, Nagasaki University Graduate School of Biomedical Sciences, Japan.

Plasma cell leukemia (PCL) is a rare variant of multiple myeloma. The detection of plasma cells in the peripheral blood and monoclonal protein in the serum or urine is important for the diagnosis of PCL. However, it is sometimes difficult to diagnose PCL in patients with atypical plasma cell morphology and/or those without detectable monoclonal protein. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2169/internalmedicine.2472-18DOI Listing

Bortezomib for the Treatment of Hematologic Malignancies: 15 Years Later.

Drugs R D 2019 Apr 16. Epub 2019 Apr 16.

Department of Hematology, Medical University of Lodz, Ul. Ciolkowskiego 2, 93-510, Lodz, Poland.

Bortezomib is a dipeptidyl boronic acid that selectively inhibits the ubiquitin proteasome pathway, which plays a role in the degradation of many intracellular proteins. It is the first-in-class selective and reversible inhibitor of the 26S proteasome, with antiproliferative and antitumor activity. It exerts its anti-neoplastic action mainly via the inhibition of the nuclear factor-κB pathway components associated with cell proliferation, apoptosis, and angiogenesis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40268-019-0269-9DOI Listing

Monitoring tumour burden and therapeutic response through analysis of circulating tumour DNA and extracellular RNA in multiple myeloma patients.

Leukemia 2019 Apr 16. Epub 2019 Apr 16.

Myeloma Research Group, Australian Centre for Blood Diseases, Alfred Hospital-Monash University, Melbourne, VIC, Australia.

Monitoring tumour burden and therapeutic response through analyses of circulating cell-free tumour DNA (ctDNA) and extracellular RNA (exRNA) in multiple myeloma (MM) patients were performed in a Phase Ib trial of 24 relapsed/refractory patients receiving oral azacitidine in combination with lenalidomide and dexamethasone. Mutational characterisation of paired BM and PL samples at study entry identified that patients with a higher number of mutations or a higher mutational fractional abundance in PL had significantly shorter overall survival (OS) (p = 0.005 and p = 0. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41375-019-0469-xDOI Listing

Treatment of Refractory ALK Rearranged Anaplastic Large Cell Lymphoma With Alectinib.

Clin Lymphoma Myeloma Leuk 2019 Mar 11. Epub 2019 Mar 11.

Division of Hematology/Oncology, University of Virginia, Charlottesville, VA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2019.03.001DOI Listing
March 2019
1 Read

NMR Methods for Quantitative Isotopomer Rates in Real-Time Metabolism of Cells.

Chembiochem 2019 Apr 16. Epub 2019 Apr 16.

University of Birmingham, HWB-NMR, CR UK Institute of Cancer Studies, Vincent Drive, Edgbaston, B15 2TT, Birmingham, UNITED KINGDOM.

Tracer-based metabolism is becoming increasingly important to study metabolic mechanisms in cells. NMR offers several approaches to measure label incorporation in metabolites, including 13C and 1H-detected spectra. The latter are generally more sensitive but quantification depends on the proton carbon 1JCH coupling constant which varies significantly between different metabolites. Read More

View Article

Download full-text PDF

Source
https://onlinelibrary.wiley.com/doi/abs/10.1002/cbic.2019000
Publisher Site
http://dx.doi.org/10.1002/cbic.201900084DOI Listing
April 2019
2 Reads

Successful hematopoietic stem-cell mobilization with plerixafor plus granulocyte-colony stimulating factor in multiple myeloma patients treated with pomalidomide.

Int J Hematol 2019 Apr 13. Epub 2019 Apr 13.

Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, 3-18-22 Honkomagome, Bunkyo-ku, Tokyo, 113-8677, Japan.

Autologous stem-cell transplantation is an effective procedure for the treatment of multiple myeloma, and involves the collection of hematopoietic stem cells (HSCs). However, in some patients, HSCs in the bone marrow fail to mobilize. Pomalidomide upregulates CXCR4 in hematopoietic stem cells, in a manner similar to that of lenalidomide, and is, thus, likely to have a negative impact on hematopoietic stem-cell mobilization in multiple myeloma patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12185-019-02622-0DOI Listing
April 2019
1 Read

Effects of triptolide on bone marrow-derived mesenchymal stem cells from patients with multiple myeloma.

Exp Ther Med 2019 May 12;17(5):3291-3298. Epub 2019 Mar 12.

Department of Hematology, Tongde Hospital of Zhejiang Province, Hangzhou, Zhejiang 310012, P.R. China.

Triptolide (TPL), an extract of the Chinese herb Hook F, is a potent anti-inflammatory agent that further possesses anticancer activity. Its antiproliferative effects are well established. Only few studies have focused on TPL as a potential treatment in multiple myeloma (MM). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3892/etm.2019.7373DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6447813PMC
May 2019
1 Read

Spindle Cell Myeloma: A Masquerader.

Indian J Hematol Blood Transfus 2019 Apr 13;35(2):382-383. Epub 2019 Feb 13.

Department of Hematology, I Block, Sanjay Gandhi Post Graduate Institute of Medical Sciences (SGPGIMS), Raibareily Road, Lucknow, 226014 India.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s12288-019-01090-0
Publisher Site
http://dx.doi.org/10.1007/s12288-019-01090-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6439119PMC
April 2019
6 Reads

Clinical Outcomes in Multiple Myeloma Post-Autologous Transplantation-A Single Centre Experience.

Indian J Hematol Blood Transfus 2019 Apr 21;35(2):215-222. Epub 2018 Jul 21.

Department of Haematology, Christian Medical College, Vellore, 632004 India.

There is paucity of data from developing countries on the clinical outcomes in myeloma post-autologous transplantation. In this retrospective study, we used hospital records to retrieve data of patients with multiple myeloma undergoing autologous stem cell transplantation (ASCT) from January 1995 to December 2014 at our centre. During the study period, 245 patients underwent ASCT for myeloma. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s12288-018-0989-y
Publisher Site
http://dx.doi.org/10.1007/s12288-018-0989-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6438994PMC
April 2019
2 Reads

Stem Cell Transplantation in Multiple Myeloma: Very Much Alive and Kicking.

Indian J Hematol Blood Transfus 2019 Apr 13;35(2):205-207. Epub 2019 Mar 13.

2Department of Internal Medicine, PGIMER, Chandigarh, 160012 India.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12288-019-01111-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6438993PMC
April 2019
2 Reads

Metformin inhibits IL-6 signaling by decreasing IL-6R expression on multiple myeloma cells.

Leukemia 2019 Apr 15. Epub 2019 Apr 15.

Division of Hematology, Mayo Clinic, Rochester, MN, 55905, USA.

IL-6 signaling plays a crucial role in the pathogenesis of a number of diseases, including multiple myeloma, primary amyloidosis, cytokine release syndrome and other inflammatory conditions. It is central for the growth and survival of malignant plasma cells. IL-6R and IL-6ST receptors transduce IL-6 signaling. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41375-019-0470-4DOI Listing
April 2019
1 Read

Exploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed/refractory multiple myeloma.

Proc Natl Acad Sci U S A 2019 Apr 15. Epub 2019 Apr 15.

State Key Laboratory of Medical Genomics, Shanghai Institute of Hematology, National Research Center for Translational Medicine, Ruijin Hospital affiliated with Shanghai Jiao Tong University School of Medicine, 200025 Shanghai, China;

Relapsed and refractory (R/R) multiple myeloma (MM) patients have very poor prognosis. Chimeric antigen receptor modified T (CAR T) cells is an emerging approach in treating hematopoietic malignancies. Here we conducted the clinical trial of a biepitope-targeting CAR T against B cell maturation antigen (BCMA) (LCAR-B38M) in 17 R/R MM cases. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1073/pnas.1819745116DOI Listing
April 2019
2 Reads

When Monoclonal Gammopathy is of Renal Significance: A Case Study of Crystalglobulinemia From Chicago Multiple Myeloma Rounds.

Clin Lymphoma Myeloma Leuk 2019 Mar 8. Epub 2019 Mar 8.

Division of Hematology, Oncology and Stem Cell Transplant, Rush University Medical Center, Chicago, IL. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2019.02.008DOI Listing
March 2019
1 Read

SOHO State of the Art Updates and Next Questions: Myelofibrosis.

Clin Lymphoma Myeloma Leuk 2019 Mar 22. Epub 2019 Mar 22.

University of Michigan Rogel Cancer Center, Ann Arbor, MI.

The discovery of a mutation in the Janus Kinase 2 gene in 2005 spurred significant progress in the field of myeloproliferative neoplasms. A comprehensive description of genomic factors at play in the malignant clone in myeloproliferative neoplasms, particularly myelofibrosis (MF), have recently led to more precise, personalized prognostic tools. Despite this, understanding of the disease pathogenesis remains relatively limited. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S21522650193017
Publisher Site
http://dx.doi.org/10.1016/j.clml.2019.03.011DOI Listing
March 2019
2 Reads

Clinicopathological spectrum of renal parenchymal involvement in B-cell lymphoproliferative disorders.

Kidney Int 2019 Mar 15. Epub 2019 Mar 15.

Department of Nephrology and Renal Transplantation, Centre Hospitalier Universitaire, Université de Poitiers, Poitiers, France; CNRS UMR 7276, INSERM UMR 1262, Université de Limoges, Limoges, France; INSERM CIC 1402, Centre Hospitalier Universitaire, Poitiers, France.

The clinicopathological characteristics of kidney infiltration in B-cell lymphoproliferative disorders remain poorly described. We retrospectively studied 52 adults with biopsy-proven malignant B-cell kidney infiltration, including Waldenström's macroglobulinemia (n=21), chronic lymphocytic leukemia (n=11), diffuse large B-cell lymphoma (DLBCL) (n=8), other lymphoma (n=11), and multiple myeloma (n=1). Kidney disease varied according to the underlying lymphoproliferative disorder. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.kint.2019.01.027DOI Listing
March 2019
1 Read

HDAC Inhibitors Exert Anti-Myeloma Effects through Multiple Modes of Action.

Cancers (Basel) 2019 Apr 4;11(4). Epub 2019 Apr 4.

Department of Hematology/Oncology, Research Hospital, Institute of Medical Science, University of Tokyo, Tokyo 108-8639, Japan.

HDACs are critical regulators of gene expression that function through histone modification. Non-histone proteins and histones are targeted by these proteins and the inhibition of HDACs results in various biological effects. Moreover, the aberrant expression and function of these proteins is thought to be related to the pathogenesis of multiple myeloma (MM) and several inhibitors have been introduced or clinically tested. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/cancers11040475DOI Listing
April 2019
1 Read

The role of long non-coding RNAs in multiple myeloma.

Eur J Haematol 2019 Apr 15. Epub 2019 Apr 15.

Henan Institute of Haematology, Department of Hematology, Henan Cancer Hospital, The Affliated Cancer Hospital of Zhengzhou University, Zhengzhou, China.

Multiple myeloma(MM) is still an incurable disease and its pathogenesis involves cytogenetics and epigenetics. In recent years, the roles of long non-coding RNAs (lncRNAs) in MM have been deeply studied by scholars. LncRNAs are defined as a class of nonprotein-coding transcripts greater than 200 nucleotides in length, which are involved in a large spectrum of biological processes, including proliferation, differentiation, apoptosis, invasion and chromatin remodeling. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ejh.13237DOI Listing
April 2019
1 Read

Is there still a role for stem cell transplantation in multiple myeloma?

Cancer 2019 Apr 15. Epub 2019 Apr 15.

Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, Georgia.

High-dose chemotherapy and autologous stem cell transplantation (ASCT) are a standard of care for transplant-eligible patients with newly diagnosed multiple myeloma (MM). The introduction of novel agents, which range from immunomodulatory drugs and proteasome inhibitors to monoclonal antibodies and have now been integrated into both induction and salvage regimens, has dramatically revolutionized the treatment landscape of MM and challenged the role of high-dose chemotherapy and ASCT in treating MM. These advances have led to a number of provocative questions. Read More

View Article

Download full-text PDF

Source
https://onlinelibrary.wiley.com/doi/abs/10.1002/cncr.32060
Publisher Site
http://dx.doi.org/10.1002/cncr.32060DOI Listing
April 2019
2 Reads

Using Stakeholder Engagement to Overcome Barriers to Implementing Patient-reported Outcomes (PROs) in Cancer Care Delivery: Approaches From 3 Prospective Studies.

Med Care 2019 May;57 Suppl 5 Suppl 1:S92-S99

Department of Health Policy and Management.

Introduction: Patient-reported outcome (PRO) measures used during cancer care delivery improve communication about symptoms between patients and clinicians and reduce service utilization for uncontrolled symptoms. However, uptake of PROs in routine cancer care has been slow. In this paper, we describe stakeholder engagement activities used to overcome barriers to implementing PROs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MLR.0000000000001103DOI Listing
May 2019
2 Reads

68Ga CXCR-4 PET/CT Imaging in an Atypical Case of Extramedullary Plasmacytoma Mimicking as Renal Cell Carcinoma.

Clin Nucl Med 2019 Apr 12. Epub 2019 Apr 12.

Nephrology Post Graduate Institute of Medical Education and Research, Chandigarh, India.

Multiple-myeloma (MM) is a malignant plasma cell proliferation disorder and the second most common blood malignancy after non-Hodgkin lymphoma. The chemokine (CXCR-4) receptor analogues are the newer agents being postulated for myeloma imaging and have shown good diagnostic performance. We report a case of plasmacytoma with suspicious renal cell carcinoma, in whom Ga CXCR-4 PET/CT revealed tracer-avid lesion in the left perinephric region. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/RLU.0000000000002574DOI Listing
April 2019
1 Read

Bone Marrow Aspirate Clot: A Useful Technique in Diagnosis and Follow-Up of Hematological Disorders.

Case Rep Hematol 2019 10;2019:7590948. Epub 2019 Mar 10.

São Paulo State University (UNESP), Medical School of Botucatu, Department of Pathology, Botucatu, SP, Brazil.

Bone marrow biopsy is a diagnostic tool largely used in the evaluation of a broad number of disorders that could affect the hematopoietic system. Differently, bone marrow aspirate clot technique is rarely performed even though it has been described in literature. Here, we highlight the utility of the bone marrow aspirate clot, exemplifying through the discussion of three clinical cases in which this technique was used for diagnosis and follow-up purposes: megaloblastic hemopathy, multiple myeloma, and chronic lymphocytic leukemia. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2019/7590948DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6431525PMC
March 2019
1 Read

Mogamulizumab for the Treatment of Adult T-cell Leukemia/Lymphoma.

Clin Lymphoma Myeloma Leuk 2019 Mar 23. Epub 2019 Mar 23.

Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine Saga University, Saga, Japan; Department of Drug Discovery and Biomedical Sciences, Faculty of Medicine Saga University, Saga, Japan.

Mogamulizumab, a defucosylated humanized monoclonal antibody against the C-C chemokine receptor 4 (CCR4), has been approved for the treatment of relapsed adult T-cell leukemia/lymphoma (ATL). Compared with conventional chemotherapy, mogamulizumab monotherapy displayed more efficacy in relapsed ATL, making mogamulizumab a promising therapeutic agent. However, mogamulizumab could increase graft-versus-host disease, resulting in poor survival outcome in the allogenic stem cell transplant (allo-SCT) setting. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2019.03.004DOI Listing
March 2019
1 Read

NICE guidance on daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma.

Lancet Oncol 2019 Apr 10. Epub 2019 Apr 10.

Addenbrooke's Hospital, Cambridge, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(19)30222-0DOI Listing
April 2019
1 Read

Combined CD28 and 4-1BB costimulation potentiates affinity-tuned Chimeric Antigen Receptor-engineered T cells.

Clin Cancer Res 2019 Apr 12. Epub 2019 Apr 12.

Hematology, Amsterdam University Medical Centers, VUmc

Purpose: Targeting non-specific, tumor associated antigens (TAA) with chimeric antigen receptors (CARs) requires specific attention to restrict possible detrimental on-target/off-tumor effects. A reduced affinity may direct CAR-engineered T (CAR-T) cells to tumor cells expressing high TAA levels while sparing low expressing normal tissues. However, decreasing the affinity of the CAR-target binding may compromise the overall anti-tumor effects. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-18-2559DOI Listing
April 2019
1 Read

Myeloid-derived suppressor cells endow stem-like qualities to multiple myeloma cells by inducing piRNA-823 expression and DNMT3B activation.

Mol Cancer 2019 Apr 13;18(1):88. Epub 2019 Apr 13.

Institute of Hematology, Union Hospital,Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.

Background: Myeloid-derived suppressor cells (MDSCs) and cancer stem cells (CSCs) are two important cellular components in the tumor microenvironment, which may modify the cancer phenotype and affect patient survival. However, the crosstalk between MDSCs and multiple myeloma stem cells (MMSCs) are relatively poorly understood.

Methods: The frequencies of granulocytic-MDSCs (G-MDSCs) in MM patients were detected by flow cytometry and their association with the disease stage and patient survival were analyzed. Read More

View Article

Download full-text PDF

Source
https://molecular-cancer.biomedcentral.com/articles/10.1186/
Publisher Site
http://dx.doi.org/10.1186/s12943-019-1011-5DOI Listing
April 2019
2 Reads

Bone tumours of the clavicle: Histopathological, anatomical and epidemiological analysis of 113 cases.

J Bone Oncol 2019 Jun 6;16:100229. Epub 2019 Mar 6.

Department of Pediatric Orthopaedic Surgery, Children's Hospital Hamburg-Altona, Hamburg, Germany.

Backround: This retrospective study aimed to determine the frequency of bone tumours of the clavicle and their histopathological, anatomical and epidemiological characteristics in a large case series.

Methods: The records of 327 lesions of the clavicle collected from 1976 to 2018 in our bone tumour registry and institute of pathology were reviewed. Following data were evaluated: age, gender, side, radiological assessment, tumour location within the clavicle, and histopathological findings. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jbo.2019.100229DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6439286PMC

Risk of relapse of multiple myeloma following kidney transplantation.

Clin Kidney J 2019 Apr 25;12(2):216-223. Epub 2019 Jan 25.

King's College Hospital NHS Trust, London, UK.

Background: Autologous stem cell transplantation (ASCT) and novel therapies have improved the prognosis for patients with multiple myeloma (MM). For those who undergo ASCT while on dialysis, a similar survival compared with the overall MM population has been reported. Therefore, for patients achieving remission following ASCT, kidney transplantation is an attractive option, offering an improved quality of life and significant economic advantage. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ckj/sfy137DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6452174PMC
April 2019
1 Read

Multiple myeloma and kidney transplantation: the beginning of a new era.

Clin Kidney J 2019 Apr 1;12(2):213-215. Epub 2019 Mar 1.

Division of Hematology, Department of Medicine, College of Medicine, Mayo Clinic, Rochester, MN, USA.

The introduction of several novel therapeutic agents has improved the outcome in multiple myeloma (MM) patients including those with chronic kidney disease, and it is predicted that MM will become a curable disease in a substantial subset of MM patients. While in the past-because of inferior posttransplant outcomes-renal transplantation was not offered to MM patients, recent data suggest that renal transplantation is a viable treatment option in patients treated with modern anti-myeloma induction therapy followed by autologous stem cell transplantation achieving durable complete responses. The article of Shah, Ibrahim, Delaney . Read More

View Article

Download full-text PDF

Source
https://academic.oup.com/ckj/article/12/2/213/5368138
Publisher Site
http://dx.doi.org/10.1093/ckj/sfz003DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6452187PMC
April 2019
6 Reads

The homeobox transcription factor MEIS2 is a regulator of cancer cell survival and IMiDs activity in Multiple Myeloma: modulation by Bromodomain and Extra-Terminal (BET) protein inhibitors.

Cell Death Dis 2019 Apr 11;10(4):324. Epub 2019 Apr 11.

Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy.

The transcription factor Myeloid Ecotropic Insertion Site 2 (MEIS2) has been identified as a cellular substrate of the E3-ubiquitin ligase complex CRL4-cereblon (CRBN) in crystal structure and by biochemical screen. Emerging evidence suggests that IMiDs can block MEIS2 from binding to CRBN facilitating the subsequent activation of a CRBN-E3-ubiquitin ligase activity and proteasome-mediated degradation of critical substrates regulators of Multiple Myeloma (MM) cell survival and proliferation. Bromodomain and Extra-Terminal (BET) family of proteins are important epigenetic regulators involved in promoting gene expression of several oncogenes, and many studies have revealed important anticancer activities mediated by BET inhibitors (BETi) in hematologic malignancies including MM. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41419-019-1562-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6459881PMC
April 2019
1 Read